Literature DB >> 23249973

Pleomorphic xanthoastrocytoma: magnetic resonance imaging findings in a series of cases with histopathological confirmation.

Vinícius Trindade Gonçalves1, Fabiano Reis, Luciano de Souza Queiroz, Marcondes França.   

Abstract

Pleomorphic xanthoastrocytoma (PXA) is a rare glioma. This paper aimed to analyze magnetic resonance imaging (MRI) characteristics in a series of patients diagnosed with PXA. We analyzed MRI findings in 9 patients with histopathologic diagnosis of PXA in our department over the last 12 years. The mean age of patients was 27.3 years. Cortical location was observed in all cases. The lesion imaging was solid-cystic in six cases. In eight cases, the solid component presented hypo or isointense on T1 and iso or hyperintense on T2. Contrast enhancement in the solid component was observed in eight cases. The observed imaging pattern of PXA was superficial location with leptomeningeal involvement, solid-cystic pattern and contrast enhancement in the solid component. We should consider that the association between PXA and other cortical tumors may occur, particularly, with gangliogliomas, which tend to be the main differential diagnosis in MRI.

Entities:  

Mesh:

Year:  2012        PMID: 23249973     DOI: 10.1590/s0004-282x2012005000016

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  9 in total

Review 1.  MR imaging of brain pilocytic astrocytoma: beyond the stereotype of benign astrocytoma.

Authors:  Simona Gaudino; Matia Martucci; Rosellina Russo; Emiliano Visconti; Emma Gangemi; Francesco D'Argento; Tommaso Verdolotti; Libero Lauriola; Cesare Colosimo
Journal:  Childs Nerv Syst       Date:  2016-10-18       Impact factor: 1.475

2.  Pleomorphic xanthoastrocytoma of childhood: MR imaging and diffusion MR imaging features.

Authors:  W Moore; D Mathis; L Gargan; D C Bowers; L J Klesse; L Margraf; K Koral
Journal:  AJNR Am J Neuroradiol       Date:  2014-07-03       Impact factor: 3.825

3.  Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2013-06-12       Impact factor: 4.130

4.  Parieto-temporal pleomorphic xanthoastrocytoma in a black African child.

Authors:  Aaron Musara; Kazadi K Kalangu; Maximillan N Dzowa; Wilfred Muteweye; Rudo Mutasa
Journal:  Asian J Neurosurg       Date:  2017 Apr-Jun

5.  Diagnostic accuracy of diffusion weighted imaging for differentiation of supratentorial pilocytic astrocytoma and pleomorphic xanthoastrocytoma.

Authors:  Dejun She; Jianyi Liu; Z Zeng; Z Xing; Dairong Cao
Journal:  Neuroradiology       Date:  2018-05-24       Impact factor: 2.804

6.  Demography, Pattern of Care, and Survival in Patients with Xanthoastrocytoma: A Systematic Review and Individual Patient Data Analysis of 325 Cases.

Authors:  Supriya Mallick; Prashanth Giridhar; Rony Benson; Wineeta Melgandi; Goura Kishor Rath
Journal:  J Neurosci Rural Pract       Date:  2019-10-07

7.  Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.

Authors:  Yolanda Piña; Michael J Fusco; Robert J Macaulay; Christine M Walko; Edwin Peguero; Brittany R Evernden; Keiran S Smalley; Peter Forsyth
Journal:  J Neurol       Date:  2019-11-21       Impact factor: 4.849

8.  Brain magnetic resonance imaging findings among children with epilepsy in two urban hospital settings, Kampala-Uganda: a descriptive study.

Authors:  Denise Apolot; Geoffrey Erem; Rita Nassanga; Daniel Kiggundu; Crescent Max Tumusiime; Anneth Teu; Alex Mwesigwa Mugisha; Robert Sebunya
Journal:  BMC Med Imaging       Date:  2022-10-06       Impact factor: 2.795

9.  Pleomorphic xanthoastrocytomas of adults: MRI features, molecular markers, and clinical outcomes.

Authors:  Jing Yan; Jingliang Cheng; Furong Liu; Xianzhi Liu
Journal:  Sci Rep       Date:  2018-09-24       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.